Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deni Hardiansyah

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Pharmaceutical Research|March 5, 2022
Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley RatsDeni Hardiansyah, Chee Meng Ng
Clinical and Translational Science|April 17, 2019
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell TherapyDeni Hardiansyah, Chee Meng Ng
Mabs|July 4, 2018
Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modellingDeni Hardiansyah, Chee Meng Ng
Pharmaceutical Research|February 8, 2018
Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in HumansDeni Hardiansyah, Chee Meng Ng
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 25, 2018
Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkeyDeni Hardiansyah, Chee Meng Ng
Frontiers in Nuclear Medicine|October 27, 2025
Population pharmacokinetic modeling in radiopharmaceutical therapy: a reviewDeni Hardiansyah, Bisma Barron Patrianesha, Gerhard Glatting
Zeitschrift Fur Medizinische Physik|August 12, 2022
Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects modelDeni Hardiansyah, Ade Riana, Ambros J Beer, et al.
EJNMMI Physics|February 9, 2023
Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of conceptDeni Hardiansyah, Ade Riana, Ambros J Beer, et al.
PET Clinics|October 24, 2025
Verification, Validation, and Uncertainty Quantification (VVUQ) of Physiologically Based Pharmacokinetic Models for Theranostic Digital Twins: Toward Reliable Model-Informed Treatment Planning for Radiopharmaceutical TherapiesNouran R R Zaid, Deni Hardiansyah, Tahir Yusufaly, et al.
Medical Physics|September 3, 2016
Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noiseDeni Hardiansyah, Wei Guo, Peter Kletting, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Pharmaceutical Research|March 5, 2022
Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley RatsDeni Hardiansyah, Chee Meng Ng
Clinical and Translational Science|April 17, 2019
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell TherapyDeni Hardiansyah, Chee Meng Ng
Mabs|July 4, 2018
Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modellingDeni Hardiansyah, Chee Meng Ng
Pharmaceutical Research|February 8, 2018
Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in HumansDeni Hardiansyah, Chee Meng Ng
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 25, 2018
Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkeyDeni Hardiansyah, Chee Meng Ng
Frontiers in Nuclear Medicine|October 27, 2025
Population pharmacokinetic modeling in radiopharmaceutical therapy: a reviewDeni Hardiansyah, Bisma Barron Patrianesha, Gerhard Glatting
Zeitschrift Fur Medizinische Physik|August 12, 2022
Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects modelDeni Hardiansyah, Ade Riana, Ambros J Beer, et al.
EJNMMI Physics|February 9, 2023
Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of conceptDeni Hardiansyah, Ade Riana, Ambros J Beer, et al.
PET Clinics|October 24, 2025
Verification, Validation, and Uncertainty Quantification (VVUQ) of Physiologically Based Pharmacokinetic Models for Theranostic Digital Twins: Toward Reliable Model-Informed Treatment Planning for Radiopharmaceutical TherapiesNouran R R Zaid, Deni Hardiansyah, Tahir Yusufaly, et al.
Medical Physics|September 3, 2016
Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noiseDeni Hardiansyah, Wei Guo, Peter Kletting, et al.
Pageof 4